Form 4: Galectin Therapeutics Director Kevin D. Freeman Reports Stock Purchase

Director Kevin D. Freeman reports purchasing 1,300 shares of Galectin Therapeutics at $2.64 per share.

Summary

• On October 17, 2024, Kevin D. Freeman, a director of Galectin Therapeutics Inc. (GALT), reported a transaction involving the company's common stock.
• Freeman purchased 1,300 shares at a price of $2.64 per share.
• Following the transaction, Freeman directly owns 34,769 shares.
• Freeman also indirectly owns 80,000 shares through Freeman Global Holdings LLC and 18,063 shares through an IRA.
• The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: This is a neutral report of a stock purchase by a director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The stock purchase by a director could be perceived positively by shareholders, signaling confidence in the company's future.

Key Dates